ROCHE HOLDING AG Stock Forum

$SPDR S&P Biotech ETF(XBI.US)$
$Merck & Co(MRK.US)$ x $Immunovant(IMVT.US)$
$Eli Lilly and Co(LLY.US)$ x $Cytokinetics(CYTK.US)$ (and soon)
$Regeneron Pharmaceuticals(REGN.US)$ x $Apellis Pharmaceuticals(APLS.US)$ (panache & brash)
$Gilead Sciences(GILD.US)$ x %$Madrigal Pharmaceuticals(MDGL.US)$ (liver king)
$Bristol-Myers Squibb(BMY.US)$ x $Iovance Biotherapeutics(IOVA.US)$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US)$ x $Merus(MRUS.US)$ (partner n...

$Pfizer(PFE.US)$  Phase 3
$BioCardia(BCDA.US)$  Phase 3
$Atea Pharmaceuticals(AVIR.US)$  Phase 3
$Crinetics(CRNX.US)$  Phase 3
$Axsome Therapeutics(AXSM.US)$  Phase 3
$ROCHE HOLDING AG(RHHBY.US)$  Phase 3
$ACADIA Pharmaceuticals(ACAD.US)$  Phase 3
$Sellas Life Sciences(SLS.US)$  Phase 3
$Aquestive Therapeutics(AQST.US)$  Phase 3
$Jaguar Health(JAGX.US)$  Phase 3
$Novocure(NVCR.US)$  Phase 3
$Johnson & Johnson(JNJ.US)$  Phase 3

Since the beginning of this year, $NVIDIA(NVDA.US)$ has been leading a group of semiconductor and AI stocks to further rise in response to the breakthroughs in AI technology and a booming industry outlook. However, an increasing number of investors have started to fret over the potential risks behind the high valuations of AI stocks and are scouting for alternative investment opportunities. Some of them have shifted their focus to biotech stocks...

🎯 Ph 3 readouts in Q1 2024...
$Pfizer(PFE.US)$  Phase 3
$Palatin Technologies(PTN.US)$  Phase 3
$Annovis Bio(ANVS.US)$  Phase 3
$BioCardia(BCDA.US)$  Phase 3
$Atea Pharmaceuticals(AVIR.US)$  Phase 3
$Ironwood Pharmaceuticals(IRWD.US)$  Phase 3
$Alnylam Pharmaceuticals(ALNY.US)$  Phase 3
$Axsome Therapeutics(AXSM.US)$  Phase 3
$$Novocure(NVCR.US)$  Phase 3
$ROCHE HOLDING AG(RHHBY.US)$  Phase 3
$FibroGen(FGEN.US)$  Phase 3
$ACADIA Pharmaceuticals(ACAD.US)$  Phase 3
$Sellas Life Sciences(SLS.US)$...

4 FDA approvals last week
1 PDUFA event left in Feb 2024
Last week’s PDUFAs:
$AstraZeneca(AZN.US)$ : Approved 2/16
⇒ Tagrisso (osimertinib) + chemotherapy
⇒ NSCLC
⇒ sNDA
⇒ PDUFA: Q1 2024
$Iovance Biotherapeutics(IOVA.US)$ : Approved 2/16
⇒  AMTAGVI™ (lifileucel)
⇒ Melanoma
⇒ BLA
⇒ PDUFA: 02/24/24
$ROCHE HOLDING AG(RHHBY.US)$ : Approved 2/16
⇒ Xolair® (omalizumab)
⇒ IgE-mediated food allergy
⇒ sBLA
⇒ PDUFA: Q1 2024
$IPSEY & $Merrimack Pharmaceuticals(MACK.US)$ : Approved 2/13
⇒ ...

$Pfizer(PFE.US)$  Phase 3
$Regenxbio(RGNX.US)$  Phase 3
$Annovis Bio(ANVS.US)$  Phase 3
$Atea Pharmaceuticals(AVIR.US)$  Phase 3
$Ironwood Pharmaceuticals(IRWD.US)$  Phase 3
$Alnylam Pharmaceuticals(ALNY.US)$  Phase 3
$Vertex Pharmaceuticals(VRTX.US)$  Phase 3
$KalVista Pharmaceuticals(KALV.US)$  Phase 3
$Axsome Therapeutics(AXSM.US)$  Phase 3
$Novocure(NVCR.US)$  Phase 3
$ROCHE HOLDING AG(RHHBY.US)$  Phase 3
$FibroGen(FGEN.US)$  Phase 3
$Applied Therapeutics(APLT.US)$  Phase 3
$ACADIA Pharmaceuticals(ACAD.US)$  Phase 3...